PF-06835919
Based on 1 Customer Validation
PF-06835919 (Ketohexokinase inhibitor 1) is a ketohexokinase (KHK) inhibitor, with IC50 values of 0.028 μM and 0.17 μM against human KHK-C and KHK-A, respectively, and an IC50 value of 0.21 μM against rat KHK. PF-06835919 blocks fructose (HY-N0395) phosphorylation and fructose metabolism. PF-06835919 can be used for research on metabolic dysfunction-associated steatotic liver disease, type 2 diabetes, hereditary fructose intolerance, and related conditions.
For research use only. We do not sell to patients.
- Purity: 99.53%
- CAS No.: 2102501-84-6
- Formula: C16H19F3N4O2
- Molecular Weight:356.34
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
Metabolism/Protease Compound Library
HY-L012
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Metabolic Enzyme Compound Library
HY-L146
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
IC50: 8.4 nM (KHK-C), 66 nM (KHK-A)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | IC50 |
>150 μM
Compound: 2; PF-06835919
|
Toxicity in human Primary hepatocyte incubated for 48 hrs by Celltiter-Glo assay
Toxicity in human Primary hepatocyte incubated for 48 hrs by Celltiter-Glo assay
|
[PMID: 37766386] |
| HepG2 | IC50 |
>150 μM
Compound: 2; PF-06835919
|
Cytotoxicity against human HepG2 cells measured after 48 hrs by microscopy based analysis
Cytotoxicity against human HepG2 cells measured after 48 hrs by microscopy based analysis
|
[PMID: 37766386] |
| HepG2 | IC50 |
>150 μM
Compound: 2; PF-06835919
|
Mitotoxicity in human HepG2 cells incubated for 2 hrs by Celltiter-Glo assay
Mitotoxicity in human HepG2 cells incubated for 2 hrs by Celltiter-Glo assay
|
[PMID: 37766386] |
| HepG2 | IC50 |
146 nM
Compound: 2; PF-06835919
|
Antiproliferative activity against human HepG2 cells incubated for 3 hrs by LC-MS analysis
Antiproliferative activity against human HepG2 cells incubated for 3 hrs by LC-MS analysis
|
[PMID: 37766386] |
PF-06835919 reduces steatosis and fibrosis in human hepatocyte-non-parenchymal cell co-cultures exposed to fructose[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2102501-84-6
-
Appearance Solid
-
Molecular Weight 356.34
-
Formula C16H19F3N4O2
-
Color White to off-white
-
SMILES
O=C(C[C@H]1[C@@]2(CN(C[C@]12[H])C3=NC(N4[C@H](CC4)C)=NC(C(F)(F)F)=C3)[H])O
-
Synonyms
Ketohexokinase inhibitor 1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (280.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.84 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.84 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 1% DMSO 99% Saline
Solubility: 0.5 mg/mL (1.40 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
A 384-well format on a assay plate is used in the assay and monitored by UV-vis spectroscopy in continuous mode at room temperature (rt). Compounds (Ketohexokinase inhibitor 1) are prepared in DMSO as 4 mM stocks, diluted using an 11-point half-log scheme on a Biomek FX, and incubated at rt for 30 minutes with the reaction mixture containing 50 mM HEPES, pH 7.4, 140 mM KCl, 3.5 mM MgCl2, 0.8 mM fructose, 2 mM TCEP, 0.8 mM PEP, 0.7 mM NADH, 0.01% Triton X-100, 30 U/mL pyruvate kinase-lactate dehydrogenase, and 10 nM purified KHK-C. The compound concentration in each well ranged from 1 nM to 100 μM. The reaction is initiated with the addition of 0.2 mM ATP. The absorbance is measured for 30 minutes on a SpectraMax reader after ATP is added. The concentrations provided are based on the final mixture volume of 40 μL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8063 mL | 14.0315 mL | 28.0631 mL | 70.1577 mL |
| 5 mM | 0.5613 mL | 2.8063 mL | 5.6126 mL | 14.0315 mL | |
| 10 mM | 0.2806 mL | 1.4032 mL | 2.8063 mL | 7.0158 mL | |
| 15 mM | 0.1871 mL | 0.9354 mL | 1.8709 mL | 4.6772 mL | |
| 20 mM | 0.1403 mL | 0.7016 mL | 1.4032 mL | 3.5079 mL | |
| 25 mM | 0.1123 mL | 0.5613 mL | 1.1225 mL | 2.8063 mL | |
| 30 mM | 0.0935 mL | 0.4677 mL | 0.9354 mL | 2.3386 mL | |
| 40 mM | 0.0702 mL | 0.3508 mL | 0.7016 mL | 1.7539 mL | |
| 50 mM | 0.0561 mL | 0.2806 mL | 0.5613 mL | 1.4032 mL | |
| 60 mM | 0.0468 mL | 0.2339 mL | 0.4677 mL | 1.1693 mL | |
| 80 mM | 0.0351 mL | 0.1754 mL | 0.3508 mL | 0.8770 mL | |
| 100 mM | 0.0281 mL | 0.1403 mL | 0.2806 mL | 0.7016 mL |
PF-06835919 Related Classifications
HY-U00461 Related Classifications
Powered by Bioz
- PF-06835919
- 2102501-84-6
- Ketohexokinase inhibitor 1
- PF06835919
- PF 06835919
- Ketohexokinase inhibitor1
- Ketohexokinase inhibitor-1
- Ketohexokinase
- type 2 diabetes
- ketohexokinase
- hereditary fructose intolerance
- type 2 diabetes mellitus
- metabolic dysfunction-associated steatotic liver disease
- fructose phosphorylation
- KHK-C
- fructose metabolism
- human hepatocyte-non-parenchymal cell co-cultures
- KHK-A
- Inhibitor
- inhibitor
- inhibit